Glucose Metabolism Reprogramming in Gastric Cancer: Implications for Tumor Progression and Drug Resistance

A new study has shed light on the key mechanisms driving gastric cancer progression, immune evasion, and treatment resistance. According to the research, glucose metabolism reprogramming plays a pivotal role in promoting tumor progression, immune evasion, and treatment resistance in gastric cancer. The study, conducted by a team of researchers from Southwest Medical University, highlights the importance of targeting glucose metabolism as a promising strategy for developing personalized therapies and improving outcomes in gastric cancer patients.

Key Takeaways:

• Gastric cancer is a leading cause of cancer-related mortality worldwide, with advanced stages often showing limited therapeutic response and frequent drug resistance.
• Glucose metabolism reprogramming is a pivotal mechanism promoting tumor progression, immune evasion, and treatment resistance in gastric cancer.
• The study highlights clinically relevant mechanisms such as lactate-mediated immunosuppression-via polarization of Tregs and M2 macrophages-and metabolic adaptations that drive chemotherapy resistance.
• Targeting metabolic reprogramming represents a promising strategy for developing personalized therapies and improving outcomes in gastric cancer patients.
• Further translational and clinical studies are urgently needed to validate these metabolic pathways as therapeutic targets.
• The research provides a mechanistic basis for targeting glucose metabolism to overcome drug resistance, suppress metastasis, and enhance immunotherapy efficacy in gastric cancer.

Statistics:

• Gastric cancer accounts for 15% of all cancer-related deaths worldwide (1)
• Glucose metabolism reprogramming is a key mechanism driving tumor progression in gastric cancer, with glycolysis, gluconeogenesis, and the pentose phosphate pathway playing critical roles (2)
• Lactate-mediated immunosuppression via polarization of Tregs and M2 macrophages drives chemotherapy resistance in gastric cancer (3)
• Targeting metabolic reprogramming can improve outcomes in gastric cancer patients by enhancing immunotherapy efficacy and suppressing metastasis.

Sources:

(1) International Agency for Research on Cancer, "Globocan 2020: Cancer incidence and mortality worldwide." (2) International Immunopharmacology, "Glucose metabolism reprogramming in gastric cancer: Implications for tumor" (2025), 167:115630. (3) Southwest Medical University, "Study Results from Southwest Medical University Provide New Insights into Gastric Cancer (Glucose metabolism reprogramming in gastric cancer: Implications for tumor)."